メタジェンセラピューティクス
Tsuruoka, JP · 5 known investors
Metagen Therapeutics (メタジェンセラピューティクス) is a biotech venture developing fecal microbiota transplantation (FMT) therapies and medical services based on gut microbiome research, including an FMT drug candidate (MGT-006) for ulcerative colitis. Based in Japan, it operates across drug discovery and medical services and runs a stool donation platform to source raw material.
Founders & leadership
TN
Taku Nakahara代表取締役社長CEO (President & CEO)
JT
Jun TerauchiCSO
Investors · 5
Frequently asked questions
- What does メタジェンセラピューティクス do?
- Metagen Therapeutics (メタジェンセラピューティクス) is a biotech venture developing fecal microbiota transplantation (FMT) therapies and medical services based on gut microbiome research, including an FMT drug candidate (MGT-006) for ulcerative colitis. Based in Japan, it operates across drug discovery and medical services and runs a stool donation platform to source raw material.
- Who founded メタジェンセラピューティクス?
- メタジェンセラピューティクス was founded by Taku Nakahara.
- Who are メタジェンセラピューティクス's investors?
- メタジェンセラピューティクス's investors include Dentsu Ventures, Fast Track Initiative, Global Brain, MIRAI SOUZOU, Nippon Venture Capital.
- Where is メタジェンセラピューティクス headquartered?
- メタジェンセラピューティクス is headquartered in Tsuruoka, JP.